These findings suggest a possible compensatory mechanism of increased DCs infiltration in correlation to higher PD-L1 and PD-L2 expression, potentially underpinning the rationale for the effectiveness of combined PD-L1 and PD-L2 blockade therapies particularly, particularly in the treatment of MSI-H CRC patients. The gene discussed is PDCD1LG2; the disease is colorectal carcinoma.